People News

Share this article:

Eli Lilly announced that J. Michael Cook will retire from the company's board of directors, effective April 20, 2009. Cook had been the director of the board since 2005. Michael Eskew has been appointed to replace Cook as chair of the audit committee. Eskew has been a member of Lilly's board since 2008, and served on both the audit and compensation committees.

 

Cerulean Pharma, a Cambridge, MA-based biopharma focused on nanoparticle-based drugs, announced the appointment of Oliver Fetzer as president and CEO. Fetzer was also elected to the company's board of directors, and will succeed Alan Crane, who has been named chairman of the board of directors. Fetzer was most recently SVP, corporate development and research development at Cubist Pharmaceuticals.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in People Moves

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in People Moves

Monday Moves: October 20

Promotions and hires for agencies and manufacturers

Monday Moves: September 29

Promotions and hires for agencies and manufacturers

Monday Moves—July 21, 2014

Hires and promotions for Manufacturers, Agencies and Media